Medbio

Medbio's operating companies injection-mold plastic components, subassemblies, and single-use consumables for medical device OEMs. The firm specializes in cleanroom production of parts that go into orthopedic implants, surgical robotics instruments, and drug-delivery devices. Medbio does not design or own the finished devices — it builds to customer specifications under quality-system certification.

Medbio has been a portfolio company of Graham Partners, a Philadelphia-based private equity firm, since at least 2019. Graham Partners focuses on advanced manufacturing and industrial technology investments. Medbio operates as a platform that acquires additional injection-molding businesses to integrate into its network.

Medbio has publicly cited relationships with large-cap orthopedic and surgical device manufacturers headquartered in the Midwest. Stryker, the Kalamazoo-based orthopedics and robotics giant, and Zimmer Biomet, the Warsaw, Indiana implant maker, represent the type and geography of OEM customer that sits in Medbio's core supply chain (per industry concentration patterns and Medbio's stated location strategy).

Medbio uses a hybrid model: it acquires niche medical injection molders with established OEM contracts, then invests in capacity expansion and quality-system maturation to deepen those relationships. This buy-and-build approach under Graham Partners has added facilities across Michigan and New York, including the December 2024 acquisition of Polymer Conversions, which brought metal-to-plastic conversion expertise into the platform.

Medbio's plants operate certified cleanrooms that comply with ISO 13485, the quality-management standard specific to medical device manufacturing, and are FDA-registered establishments. The firm's customer base requires production within these frameworks as a condition of supplier qualification.

No. Medbio is a contract manufacturing platform company backed by institutional private equity. It does not manage family capital, make passive investments, or operate a direct-investment portfolio. The name reflects its medical-bio manufacturing focus, not a family office structure.

Each acquired facility generally retains its legacy customer contracts and engineering teams. Medbio's value-add is centralized quality-system investment and cross-site capacity coordination. OEMs operating across multiple Medbio sites can access expanded production scale without switching suppliers, which the firm presents as supply-chain continuity rather than vendor consolidation.